1-5 of 5
Manuel Litchman, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Yolanda Mahnke, PhD, Simon F. Lacey, PhD BSc, J. Joseph Melenhorst, PhD, Anne Chew, PhD, Gaurav Shah, MD, Jens Hasskarl, MD, Manuel Litchman, MD, Mariusz A. Wasik, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Alfred L. Garfall, MD, Noelle V. Frey, MDMS, Katherine T. Marcucci, PhD, Joanne Shea, RN, Holly McConville, RN, BSN, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2014) 124 (21): 3087.
https://doi.org/10.1182/blood.V124.21.3087.3087
Published: 2014
Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

David L. Porter, MD, Noelle V. Frey, MDMS, J. Joseph Melenhorst, PhD, Wei-Ting Hwang, PhD, Simon F. Lacey, PhD BSc, Pamela Shaw, PhD, Anne Chew, PhD, Stephan A. Grupp, MD PhD, James Capobianchi, Joan Gilmore, Michael Kalos, PhD, Manuel Litchman, MD, Lester Lledo, RN,MSN,CNP, Alison Wakoff Loren, MDMS, Yolanda Mahnke, PhD, Katherine T. Marcucci, PhD, Holly McConville, RN, Angela Shen, MD, Patricia A. Wood, MD PhD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2014) 124 (21): 1982.
https://doi.org/10.1182/blood.V124.21.1982.1982
Published: 2014
Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

David L. Porter, MD, Simon F. Lacey, PhD BSc, Wei-Ting Hwang, PhD, Pamela Shaw, PhD, Noelle V. Frey, MDMS, Anne Chew, PhD, Fang Chen, PhD, Michael Kalos, PhD, Vanessa Gonzalez, PhD, Katherine T. Marcucci, PhD, Shannon L Maude, MD PhD, Jan J Melenhorst, PhD, Manuel Litchman, MD, David T. Teachey, MD, Angela Shen, MD, Alfonso Quintas-Cardamas, MD, Patricia A. Wood, MD PhD, Bruce L. Levine, PhD, Carl H. June, MD, Stephan A. Grupp, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1983.
https://doi.org/10.1182/blood.V124.21.1983.1983
Published: 2014
Journal Articles

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemision, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Angela Shen, MD, Patricia A. Wood, MD, PhD, Manuel Litchman, MD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD
Journal: Blood
Blood (2013) 122 (21): 873.
https://doi.org/10.1182/blood.V122.21.873.873
Published: 2013
Journal Articles

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Stephan A Grupp, MD, PhD, Noelle V. Frey, MD, Richard Aplenc, MD, PhD, David M Barrett, MD/PhD, Anne Chew, PhD, Michael Kalos, PhD, Bruce L. Levine, PhD, Manuel Litchman, MD, Shannon L Maude, MD, PhD, Susan R. Rheingold, Angela Shen, MD, Christine Strait, David T. Teachey, MD, Patricia A. Wood, MD, PhD, David Porter, MD, Carl H. June, MD
Journal: Blood
Blood (2013) 122 (21): 67.
https://doi.org/10.1182/blood.V122.21.67.67
Published: 2013